^
Association details:
| Biomarker: | EGFR L858R + VOPP1-EGFR fusion + EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Emerging a Novel VOPP1-EGFR Fusion Coexistent With T790M as an Acquired Resistance Mechanism to Prior Icotinib and Sensitive to Osimertinib in a Patient With EGFR L858R Lung Adenocarcinoma: A Case Report
Published date:
12/22/2021
Excerpt:
In this case report, we describe a 69-year-old female who received right lobectomy and was diagnosed with pathological stage IIIA lung adenocarcinoma harboring EGFR L858R....A novel vesicular overexpressed in cancer pro-survival protein 1 (VOPP1)-EGFR fusion gene coexistent with T790M were identified by next-generation sequencing...the patient was switched to osimertinib treatment, which resulted in a progression-free survival interval of more than 11 months... the present case increases the evidence supporting use of osimertinib for treatment of NSCLC patients harboring EGFR fusion.
DOI:
https://doi.org/10.3389/fonc.2021.720819
